Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
|
|
- Philip Hicks
- 6 years ago
- Views:
Transcription
1 Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
2 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately recommend reversal strategies for the novel oral anticoagulants Be aware of agents on the horizon for the reversal of the novel oral anticoagulants
3 Case Vignette #1 A 68yom with a history of recurrent DVTs presents to the emergency department with bright red blood per rectum. He takes Warfarin 7.5 mg daily and had an INR of 2.8 in the coumadin clinic last week. He is pale and tachycardic. Repeat INR is 8 Hemoglobin and hematocrit are 5.4g/dL and 15%
4 Date of download: 1/3/2016 Copyright American College of Chest Physicians. All rights reserved. From: Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest. 2012;141(2_suppl):e44S-e88S. doi: /chest [Section 1.1] Vitamin K 1 is reduced to vitamin KH2. The major warfarin-sensitive enzyme in this reaction is the vitamin K oxide reductase mainly inhibited by the S-enantiomer of warfarin. S-warfarin is metabolized by the p450 cytochrome enzyme, CYP2C9. Reprinted with permission from Ansell et al. 8
5 Case Vignette #1 What is/are the best treatment(s) for reversal of this patient s anticoagulation? A. Fresh frozen plasma B. Oral Vitamin K C. IV Vitamin K D. Prothrombin Complex Concentrate E. IV Vitamin K and Prothrombin Complex Concentrate
6 Prothrombin Complex Concentrates
7 Prothrombin Complex Concentrates Profilnine, Bebulin & Kcentra Contain clotting factors: II, VII, IX, X Heparin and ATIII to keep inactivated Contain Proteins C, S Confers less risk of thrombosis Kcentra [package insert]. 2013
8 Prothrombin Complex Concentrates Advantages over FFP No cross matching No thawing time Less risk of viral transmission Less volume 200mL vs mL Quicker reversal of INR No risk of TRALI Babilonia, et al. Thrombosis Journal PMID:
9 PMID:
10 PMID:
11 PMID:
12 Hanke, et al. Br J Anaest PMID: Safety
13 Kcentra Clinical Considerations Kcentra Restrictions Inclusion Criteria: Treatment of life-threatening bleeding or major bleeding associated with hemodynamic instability in patients taking warfarin (including those who present with intracranial hemorrhage and declining neurologic status) Rapid correction of INR in patients receiving warfarin and who require immediate reversal for life-sustaining procedures (anticipated need within 8 hours) Exclusion Criteria: Known history of heparin-induced thrombocytopenia Disseminated intravascular coagulation is suspected Bleeding in the absence of an anticoagulant
14 Kcentra Dosing Based on INR & weight (kg) INR 2-4: 25 units/kg INR 4.1-6: 35 units/kg INR >6: 50 units/kg >1 dose not studied, not recommended Kcentra [package insert] Spahn et al. Critical Care PMID:
15 Kcentra Administration Administer within 4 hours of reconstitution Dedicated line required for administration 2 separate lines preferable (one for Vitamin K ) Administer as an 500ml/hr (15-30 minute infusion) After infusion, replace Kcentra with 100cc bag NS and run at same rate Repeat INR 30 minutes after infusion
16 CO$T Kcentra $1.34 per unit Fresh Frozen Plasma <$ unit/plasma ~$670 per vial (~500 units) $6700 for 5,000 unit dose (max dose)
17 Treatment of VKA Related Bleeding For patients with VKA-associated major bleeding, rapid reversal of anticoagulation with four-factor prothrombin complex concentrate rather than with plasma is recommended (Grade 2C). The additional use of Vitamin K 5 to 10 mg administered by slow IV infusion rather than reversal with coagulation factors alone is also recommended (Grade 2C).
18 Case Vignette #2 A 72yof with a history of rate-controlled atrial fibrillation and hypertension presents with new onset weakness. She has been on dabigatran (Pradaxa ) 220mg BID for the past year. Her last dose was administered 8 hours ago. She is hypotensive with SBPs in the 90s.
19 Date of download: 1/3/2016 Copyright American College of Chest Physicians. All rights reserved. From: New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest. 2012;141(2_suppl):e120S-e151S. doi: /chest Dabigatran
20 Case Vignette #2 A 72yof with a history of rate-controlled atrial fibrillation and hypertension presents with new onset weakness. She has been on dabigatran (Pradaxa )220mg BID for the past year. Her last dose was administered 8 hours ago. She is hypotensive with SBPs in the 90s. Imaging studies show the following:
21 Hemorrhagic Stroke
22 Case Vignette #2 A 72yof with a history of rate-controlled atrial fibrillation and hypertension presents with new onset weakness. She has been on dabigatran (Pradaxa ) 220mg BID for the past year. Her last dose was administered 8 hours ago. She is hypotensive with SBPs in the 90s. What is the best treatment option for reversal of dabigatran in this case? A. Activated charcoal B. Fresh frozen plasma C. Idarucizumab (Praxbind ) D. Hemodialysis
23 Praxbind - Idarucizumab Humanized monoclonal antibody fragment (Fab) Binds/ neutralizes dabigatran and its metabolites Eliminated in the urine Praxbind [package insert].
24 Praxbind - Idarucizumab Clinical Application FDA Accelerated Approval October 2015 Emergency Surgery/Urgent Procedure Life Threatening/Uncontrolled Bleeding Praxbind [package insert].
25 Praxbind - Idarucizumab Clinical Application Contraindications: None Not studied in patients with CrCl <30* Warnings and Precautions: Thromboembolic risk Re-elevation of coagulation parameters Hypersensitivity Fructose intolerance Praxbind [package insert].
26 Praxbind - Idarucizumab Purpose: RE-VERSE AD Trial Efficacy & Safety of Idarucizumab for dabigatran reversal Study Design: Multicenter, prospective cohort study Interim data analysis on 90 of 300 pts Each patient received two 2.5 g infusions 15 minutes apart Pollack CV, et al. N Engl J Med Aug 6;373(6):
27 Praxbind - Idarucizumab RE-VERSE AD Trial Inclusion: 18 yo and on dabigatran Group A: Life-threatening bleed Group B: Urgent procedure required Study Treatment: 5gm IV idarucizumab (2-2.5gm 50mL boluses), no more than 15 min apart Pollack CV, et al. N Engl J Med Aug 6;373(6):
28 Praxbind - Idarucizumab Primary: Endpoints Maximum percentage reversal within 4 hours administration Secondary: Restoration of hemostasis Proportion with normalization of dilute thrombin time Proportion with normalization of ecarin clotting time Reduction in concentration of unbound dabigatran Safety: All adverse events captured Pollack CV, et al. N Engl J Med Aug 6;373(6):
29 Praxbind - Idarucizumab Baseline Characteristics Patient Characteristics Age (Median) 77 Race 87% white Cr Clearance (Mean) 62 ml/min Atrial Fibrillation 96% Last dose of dabigatran (Median) 15 hr Elevated dilute thrombin time at baseline 76% Elevated ecarin clotting time at baseline 90% Pollack CV, et al. N Engl J Med Aug 6;373(6):
30 Praxbind - Idarucizumab Results 22 patients had dilute thrombin times that were within normal limits and 9 of those patients had normal ecarin-clotting times excluding these 22 pts from efficacy analysis 68 of 90 were assessed with dilute thrombin time (Group A - 40 patients and Group B - 28 patients) 81 of 90 were assessed with ecarin-clotting time (Group A - 47 patients and Group B - 34 patients). All patients received idarucizumab regardless of their inclusion in the efficacy analysis Pollack CV, et al. N Engl J Med Aug 6;373(6):
31 Praxbind - Idarucizumab Primary : Results Maximum percentage reversal in Groups A and B was 100% Reversal was evident on first sample taken after infusion Secondary: Normalization of clotting time Dilute Thrombin Time Ecarin Clotting Time Group A 98% 89% Group B 93% 88% Pollack CV, et al. N Engl J Med Aug 6;373(6):
32 Praxbind - Idarucizumab Safety Outcomes Safety Death 18/90 (20%) Serious Adverse Event 21/90 (23.3%) MI 1/90 (1%) Stroke 1/90 (1%) DVT/PE 3/90 (3.3%) Pollack CV, et al. N Engl J Med Aug 6;373(6):
33
34 Praxbind - Idarucizumab Monitoring Parameters Efficacy Monitoring: Baseline aptt, re-evaluation of aptt at 12 and 24 hours Monitor for signs and symptoms of bleeding Toxicity Monitoring: Monitor for hypersensitivity or immunogenic reactions Praxbind [package insert].
35 Praxbind - Idarucizumab Dosing: 5 g infusion Two- 2.5g/50mL (bolus,15-min apart) Limited data to support >5 g infusion Cost: NEJM Journal Watch, 11/ g/50 ml vial ~$3500 Cost per treatment: $7000 Praxbind [package insert].
36 Praxbind - Idarucizumab Conclusions Praxbind is effective in reversing dabigatran (Pradaxa ) Minimal adverse event profile Resume anticoagulation as soon as medically feasible Pollack CV, et al. N Engl J Med Aug 6;373(6):
37 Case Vignette #3 A 62yof with a history of atrial fibrillation presents with right lower quadrant abdominal pain. She takes Xarelto (rivaroxaban) 20mg daily and her last dose was 1 hour ago.
38 Date of download: 1/3/2016 Copyright American College of Chest Physicians. All rights reserved. From: New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest. 2012;141(2_suppl):e120S-e151S. doi: /chest Rivaroxaban Apixaban Edoxaban
39 Case Vignette #3 A 62yof with a history of atrial fibrillation presents with right lower quadrant abdominal pain. She takes Xarelto (rivaroxaban) 20mg daily and her last dose was 1 hour ago. She is evaluated and is found to have acute appendicitis. Emergency surgery is recommended. What are the options for anticoagulation reversal? a) Activated charcoal b) Prothrombin complex concentrate c) Andexanet alfa d) All of the above
40 Activated Charcoal Factor Xa inhibitors (FXaI) Can be effective if given within 2 hours of administration of a FXaI Repeat dose six hours after initial administration Apixaban and Rivaroxaban Package Insert
41 PCC (Kcentra) and FXaIs: Limitations in the literature More animal studies than human studies Human clotting factors behave differently in non-humans Small numbers Healthy volunteers Reversal agents merely added to blood samples Extrapolation to bleeding patients? Variable study design Different outcomes Coag assays, bleeding time, blood loss
42 PCCs FOR NOACS (HUMAN STUDIES) Author, Year N Study Design Findings Erenberg, Dabigatran or rivaroxaban po x 2.5 d Treated with 3F-PCC bolus iv Measured PT and ETP over 24 hours Marlu, Men Dabigatran or rivaroxaban po x1 Collected blood samples Treated blood (3-F PCC, rfviia, apcc) Khoo, Dabigatran+aPCC (FEIBA) Blood treated with apcc Dinklaar, Rivaroxaban+ 3F-PCC PCC added to rivaroxaban-treated samples Coagulation assays performed Korber, Rivaroxaban + PCC/rFVIIa Blood samples treated with rivaroxaban Added PCC and rviia Performed clotting assays Findings PCC reversed PT, ETP in rivaroxaban treated patients PCC did not reverse dabigatran Findings Dabigatran rfviia most effective Rivaroxaban - PCC most effective Findings apcc reversed dabigatran Findings PCC normalized thrombin generation Did not normalize PT w/ initial dose Dose of PCC required depended on type of assay Findings PCC had no effect on clotting tests rviia reversed PT and clotting factor time RIVAROXABAN: REVERSED WITH PCC IN 3/4 STUDIES Lazo-Langner, et al. Critical Care PMID:
43 Andexanet Alfa Modified recombinant Factor Xa (inactive) Derived from human Factor X High affinity for FXaI and ATIII Forms a catalytically inactive complex
44 Andexanet alfa Breakthrough therapy in 2013 Phase II, double blind, placebo controlled study completed Phase III trials with apixaban (Eliquis ), edoxaban (Savaysa ), rivaroxaban (Xarelto ) and enoxaparin (Lovenox) underway
45 ANNEXA-4 Ongoing, multicenter, prospective, open-label, singlegroup study Acute major bleeding with a factor Xa inhibitor within 18 hours Andexanet bolus(b) over minutes, followed by a 2-hour infusion (I) >7hours since administration: B-400mg, I-480mg <7hours since administration: B-800mg, I-960mg NEJM 2016;375(12):
46 ANNEXA-4 After bolus: Median anti-factor Xa activity decreased by 89%-93% 12 hours after infusion, clinical hemostasis excellent or good in 37/47 patients Thrombotic events in 12/67 patients in 30-day followup Not FDA approved NEJM 2016;375(12):
47 Ciraparantag (PER 977) Synthetic, universal small molecule antidote for heparin, LMWH and NOACs Binds and neutralizes anticoagulants Addresses need for a broad-spectrum reversal agent
48 Ciraparantag (PER 977) Phase II trials Single IV dose provided complete and sustained reversal at 10 minutes No procoagulant signal Not FDA approved.
49 Discontinue drug Mechanical compression, surgical hemostasis, transfusion of RBC or platelets (if concomitant antiplatelet use) Activated charcoal (if last dose <2h) Consider dialysis Idarucizumab (Praxbind) Discontinue drug Mechanical compression, surgical hemostasis, transfusion of RBC or platelets (if concomitant antiplatelet use) Activated charcoal (if last dose <2h) Consider PCC (Kcentra) Future: Andexanet alfa, Ciraparantag
50 Big Picture Ideas: Discontinuation of NOACs sufficient in most cases Use of specific antidotes should be restricted to emergent cases ONLY! Availability, cost and unanticipated toxicities of reversal agents are potential issues
Managing Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationIntroduction. Blood Pressure
Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationManaging Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants
Managing Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants MICHAEL E. MULLINS MD FAACT FACEP Washington University School Of Medicine Chair, BJH Anticoagulation Subcommittee Chair,
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationIdarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):
Idarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):511-520. Objective: To measure the safety of idarucizumab to reverse dabigatran anticoagulant effects
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationEverything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science
Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Center at San Antonio Department of Pharmacotherapy
More informationReversal of DOACs Breakthroughs and Their Aftermath
Reversal of DOACs Breakthroughs and Their Aftermath Geno J Merli, MD, MACP, FSVM, FHM Professor Medicine & Surgery Co-Director Jefferson Vascular Center Sidney Kimmel Medical College Thomas Jefferson University
More informationREVERSAL STRATEGIES FOR ORAL ANTICOAGULATION
REVERSAL STRATEGIES FOR ORAL ANTICOAGULATION Wesley R. Zemrak, Pharm.D., BCPS Clinical Pharmacy Specialist, Anticoagulation Maine Medical Center, Portland, ME zemraw@mmc.org 1 OBJECTIVES 1. Discuss the
More informationNew Options for Anticoagulation Reversal: A Practical Approach
New Options for Anticoagulation Reversal: A Practical Approach Hyung Wook Park Chonnam National University Hospital, Gwangju, Korea 4 NOACs Prevention of TE No. of events (%/yr..) NOAC Warfarin HR 95%
More informationLeading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient
Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationUse of Anticoagulant Reversal Agents
Use of Anticoagulant Reversal Agents Lori Shutter, MD shutterla@upmc.edu Vice Chair of Education Director, Neurocritical Care Program Professor, Critical Care Medicine, Neurology & Neurosurgery University
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationUPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center
UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center DISCLOSURE STATEMENT OF FINANCIAL INTEREST I, Vera Wilson,
More informationAdvances in Anticoagulation
May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationWelcome to the New England QIN-QIO Medication Safety Webinar!
Welcome to the New England QIN-QIO Medication Safety Webinar! Thank you for joining. Our presentation will begin shortly. If you haven t already, please dial in to the audio line: 888-895-6448 Passcode:
More informationGuideline for Treatment of Head Injury in the Anticoagulated Patient
Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationNOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations
NOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations Mark J. Alberts, MD, FAHA Hartford HealthCare Hartford, CT USA AF confers an increased
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationReversal of Oral Anticoagulation in Critical Care. Andrew C. Faust, PharmD, BCPS Critical Care Pharmacy Specialist Texas Health Presbyterian Dallas
Reversal of Oral Anticoagulation in Critical Care Andrew C. Faust, PharmD, BCPS Critical Care Pharmacy Specialist Texas Health Presbyterian Dallas Conflicts of Interest No conflicts to report Objectives
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationReversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding
Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)
More informationEndoscopy and the Anticoagulated Patient
Endoscopy and the Anticoagulated Patient John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Objectives To accurately assess the risk
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationReversal of Action: Addressing the Unmet Need for Universal Antidotes to Factor Xa Anticoagulants. Disclosures
Reversal of Action: Addressing the Unmet Need for Universal Antidotes to Factor Xa Anticoagulants Daniel Pallin, MD, MPH Harvard Medical School Brigham and Women s Hospital Boston, Massachusetts Disclosures
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationDirect Oral Anticoagulant Reversal
08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics
More informationidarucizumab 2.5g/50mL solution for injection/infusion (Praxbind ) SMC No. (1178/16) Boehringer Ingelheim Ltd
idarucizumab 2.5g/50mL solution for injection/infusion (Praxbind ) SMC No. (1178/16) Boehringer Ingelheim Ltd 05 August 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationManaging Bleeding on NOACs
Managing Bleeding on NOACs and Other Evolving ED Protocols Objectives Understand that NOACs are widely used in clinical practice Discuss the new and evolving protocols for managing bleeding in patients
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationBLOOD DISEASE RESEARCH FOUNDATION
BLOOD DISEASE RESEARCH FOUNDATION BLOOD DISEASE RESEARCH FOUNDATION The mission of Blood Disease Research Foundation is to support hematological research, e.g. by donating grants for thesis work and abstract
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationAnticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016
Review Article in Major Bleeding: Update 2016 Steve Christos, DO, MS* Robin Naples, MD * Presence Resurrection Medical Center, Department of Emergency Medicine, Chicago, Illinois Lewis Katz School of Medicine
More informationATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS
ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, THROMBOLYTIC REVERSAL IN ADULT PATIENTS Several of the below interventions are based on low-level evidence and are intended as suggestions only.
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationTreatment of anticoagulant-associated intracerebral haemorrhage
Treatment of anticoagulant-associated intracerebral haemorrhage Adrian Parry-Jones NIHR Clinician Scientist & Honorary Consultant Neurologist Manchester Academic Health Science Centre, Salford Royal NHS
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationUpdate on the Management of Cancer Associated VTE
Update on the Management of Cancer Associated VTE Jean M. Connors, MD 2018 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Associate Professor
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationFaculty. DOACs and Reversal Agents: Disclosures. Considerations for Health-System Pharmacists. Learning Objectives
Faculty DOACs and Reversal Agents: Considerations for Health-System Pharmacists Mark A. Munger, PharmD, FCCP, FACC, FHFSA Professor of Pharmacotherapy Adjunct Professor, Internal Medicine University of
More informationA Cascade of Updates: Hot Topics in Anticoagulation
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationNewer Oral Anticoagulants and Available Reversal Agents. Cara L. Leos, Pharm D, BCPS AQ Cardiology Baptist Medical Center South Montgomery, AL
Newer Oral Anticoagulants and Available Reversal Agents Cara L. Leos, Pharm D, BCPS AQ Cardiology Baptist Medical Center South Montgomery, AL Disclosure Speakers bureau Boehringer Ingelheim As each of
More informationOverview of the Direct Oral Anticoagulants
Original Article Nedaa Skeik, MD Abhishek Sethi Michele Shepherd, PharmD From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Nedaa Skeik, MD Minneapolis
More informationDisclosure and Conflict of Interest
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationIdarucizumab is produced by recombinant DNA technology in Chinese Hamster Ovary cells.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationCurrent Practice in Emergency Management
Current Practice in Emergency Management Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine Siriraj Hospital Are you ready? www.techtimes.com, www.webmd.com Outline
More informationHemostasis and Thrombosis for Primary Care Providers: An Update. Andrew D. Leavitt, MD. May 21, Topic Outline. Direct Oral Anti-Coagulants DOACs
Hemostasis and Thrombosis for Primary Care Providers: An Update 43 nd Annual Advances in Internal Medicine Andrew D. Leavitt, MD May 21, 2015 Topic Outline Direct Oral Anti-Coagulants DOACs Update and
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY
ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY Click here for the full Thrombosis Prevention Investigation and Management of Anticoagulation Guideline Click on the appropriate link below: o START
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationAgent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min
Nanik (Nayri) Hatsakorzian Pharm.D/MPH candidate 2014 Touro University College of Pharmacy CA Bleeding Reversal Agents Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes
More informationSee 17 for PATIENT COUNSELING INFORMATION.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND (idarucizumab)
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More information